Opus Genetics Reports Q2 2026 Financial Results

What Happened
On August 6, 2026, Opus Genetics, Inc. (IRD) announced its financial results for the second quarter ended June 30, 2026 via a press release. The press release was furnished with the company’s Form 8-K as Exhibit 99.1 and is incorporated by reference. The filing was signed by CEO Dr. George Magrath.

Key Details

• Filing date: August 6, 2026 (Form 8-K, Item 2.02).
• Reporting period: Quarter ended June 30, 2026 (second quarter 2026).
• Exhibit included: Press release dated August 6, 2026 (Exhibit 99.1).
• Administrative exhibits: Cover page Inline XBRL file included as Exhibit 104.1; 8-K signed by CEO Dr. George Magrath.

Why It Matters
This 8-K notifies investors that Opus Genetics has released its quarterly earnings and related financial metrics. Investors should review the attached press release (Exhibit 99.1) for details on revenue, expenses, cash position, and any commentary on operations or outlook. As a routine earnings disclosure, the filing provides timely financial information that can affect valuation and trading decisions; for fuller financial statements and additional context, look for the company’s subsequent quarterly report (Form 10-Q) or investor presentation.